Indianapolis, Ind., 2026 — Eli Lilly and Company today announced positive head-to-head Phase 3 results demonstrating that its investigational oral GLP-1 receptor agonist, orforglipron, delivered superior reductions in blood sugar and body weight compared to Novo Nordisk’s marketed therapy Rybelsus in adults with type 2 diabetes.
The findings strengthen Lilly’s regulatory and commercial positioning as it prepares for a potential FDA decision on orforglipron for obesity in the second quarter, with a diabetes filing planned later this year.
Superior Glycemic Control and Weight Reduction
In a study enrolling nearly 1,700 adults inadequately controlled on metformin, participants were randomized to receive varying doses of semaglutide (Rybelsus) or orforglipron over 52 weeks.
Orforglipron met criteria for both non-inferiority and statistical superiority across primary endpoints:
- High-dose orforglipron: Average A1C reduction of 1.9 percentage points vs. 1.5 for high-dose Rybelsus
- Low-dose orforglipron: 1.7 percentage point reduction vs. 1.2 for low-dose Rybelsus
- Weight loss (high dose): 8.2% vs. 5.3%
- Weight loss (low dose): 6.1% vs. 3.9%
The results signal a potential competitive shift in the oral GLP-1 segment, where Novo Nordisk currently maintains exclusivity.
Tolerability Trade-Offs
While efficacy endpoints favored orforglipron, higher discontinuation rates due to side effects were observed in the Lilly treatment arms. Approximately 9–10% of participants receiving orforglipron discontinued treatment due to adverse events, compared to roughly 4–5% among Rybelsus recipients.
These tolerability dynamics may factor into payer, physician and patient decision-making as the oral GLP-1 market expands.
Strategic and Market Implications
The data intensify competitive pressure on Novo Nordisk, whose semaglutide franchise generated more than $34 billion in global sales in 2025 across injectable and oral formulations.
Orforglipron’s profile suggests that Lilly could soon challenge Novo’s dominance in oral GLP-1 therapies for both diabetes and obesity. Unlike peptide-based semaglutide, orforglipron is a small molecule GLP-1 receptor agonist, offering manufacturing and scalability advantages that may influence long-term market dynamics.
Looking Ahead
Lilly plans to submit regulatory filings for diabetes later this year while awaiting an FDA decision on obesity in the coming quarter.
As competition escalates in the rapidly expanding cardiometabolic market, the critical question becomes whether superior efficacy can outweigh tolerability trade-offs in physician prescribing behavior and payer access negotiations.
If approved, orforglipron could mark a pivotal evolution in oral incretin therapy—reshaping the balance of power in one of the pharmaceutical industry’s most valuable therapeutic categories.
By
